Shares of Agilent Technologies Inc. (A) got a little lift in Monday's premarket trading. The reason? The company is opening its wallet to the tune of about $950 million to buy Biocare Medical, a player in the clinical and research pathology world.
Think of it as Agilent making a nearly billion-dollar bet that the future of its diagnostics business lies in very specific, very tiny antibodies.
What Agilent Is Buying
Biocare isn't some startup. It's an established name in pathology, particularly in the niche of immunohistochemistry (IHC) and hybridization. In simpler terms, they make the specialized tools and chemical reagents that labs use to stain tissue samples so doctors and researchers can see specific proteins or markers under a microscope. It's a critical step in diagnosing diseases like cancer.
Biocare brings a portfolio of over 300 specialized antibodies to the table, along with a track record of robust research and development. Perhaps most enticing for Agilent is Biocare's financial performance: it's been clocking double-digit revenue and profit growth since 2021.
For Agilent, this isn't just an add-on; it's a strategic muscle-building exercise. Adding Biocare's antibodies, reagents, and instruments will immediately strengthen Agilent's own IHC offerings and broaden its reach into more clinical and research labs. Agilent is banking on Biocare's existing growth in the IHC market and its efficient product innovation engine to turbocharge Agilent's ability to develop and commercialize new in-vitro diagnostic (IVD) antibodies.
The deal is expected to close in Agilent's fourth fiscal quarter of 2026, pending the usual regulatory nods. Once it does, Biocare will become part of Agilent's Life Sciences and Diagnostics Markets Group. Agilent expects the transaction to boost its revenue growth and margins in the first year, improve its mix of non-instrument revenue (which is often more stable and profitable), and become accretive to earnings per share roughly 12 months after closing. The company had about $1.76 billion in cash on hand as of late January, so it has the dry powder for this move.
The Stock Story: A Slump and a Potential Catalyst
Now, let's talk about the stock, because that's where things get interesting. Over the past year, Agilent's shares are down about 5.6%. As of the latest check, the stock was trading at $116.41. That's below its 20-day simple moving average of $123.62 and well below its 50-day average of $132.93, which paints a bearish short-term picture.
Some technical indicators hint at a possible turn. The Relative Strength Index (RSI) is sitting at a very oversold 28.41, which often precedes a bounce. However, the MACD indicator remains in bearish territory. It's a mixed bag, suggesting that investors are watching to see if strategic moves like this acquisition can shift the momentum.
The market's initial reaction was positive, with shares up 1.16% to $116.41 in premarket trading Monday.
